Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Maze Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Maze Therapeutics's regulatory disclosures and financial reporting.
Jason V. Coloma, Chief Executive Officer and Director of Maze Therapeutics (MAZE), was granted 100,000 restricted stock units (RSUs) on 09/22/2025. Each RSU converts to one share of common stock upon settlement and the grant carries a $0 per-share price. The award vests in two equal installments: 50,000 RSUs on September 1, 2026 and 50,000 RSUs on September 1, 2027, contingent on continued service. The RSUs do not have an expiration date and will be cancelled if unvested prior to vesting.
Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc. (MAZE), reported the grant of 40,000 restricted stock units (RSUs) on 09/22/2025. Each RSU represents a contingent right to one share of common stock upon settlement. The award vests in two equal installments: 20,000 RSUs vest on September 1, 2026 and 20,000 RSUs vest on September 1, 2027, subject to continued service. The RSUs have no exercise price and do not expire; they either vest or are cancelled prior to vesting. The reported ownership following the grant is 40,000 shares held directly. The Form 4 was signed by an attorney-in-fact on 09/24/2025.
Amy Bachrodt, SVP Finance of Maze Therapeutics (MAZE), was granted 22,000 restricted stock units on 09/22/2025. Each unit converts to one share of common stock upon settlement and the reporting person beneficially owns 22,000 shares after the reported transaction.
The award vests in two equal installments: 11,000 RSUs on September 1, 2026 and 11,000 RSUs on September 1, 2027, contingent on continued service. The RSUs have no expiration; they either vest or are cancelled before vesting. The Form 4 was executed by an attorney-in-fact on 09/24/2025.
Maze Therapeutics director Daniel K. Spiegelman received a stock option award on 09/22/2025. The Form 4 shows an option to buy 18,000 shares of Maze common stock at an exercise price of $23.67 per share. The option was reported as acquired on 09/22/2025 and is recorded as directly beneficially owned with 18,000 shares following the transaction. The option has an expiration/exercise date shown as 09/21/2035 and vests monthly in nine equal tranches (1/9 each) beginning with a first tranche vesting on October 1, 2025, subject to continued service. The filing was signed by an attorney-in-fact on 09/24/2025.
Catherine A. Sohn, a director of Maze Therapeutics, Inc. (MAZE), was granted a stock option on 09/22/2025 to purchase 18,000 shares of common stock at an exercise price of $23.67 per share. The option award vests monthly as to 1/9 of the total award, with the first tranche vesting on October 1, 2025, subject to continued service. The reported derivative shows 18,000 underlying shares and the reporting person is listed as owning 18,000 shares directly following the transaction. The form was signed by an attorney-in-fact on 09/24/2025.
Maze Therapeutics director Richard H. Scheller was granted a stock option for 18,000 shares on 09/22/2025 at an exercise price of $23.67 per share. The option is exercisable under an agreement that vests in nine equal monthly tranches (1/9 monthly) with the first tranche scheduled to vest on October 1, 2025, subject to continued service. The option has an expiration date shown as 09/21/2035. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/24/2025.
Maze Therapeutics director Jonathan E. Lim received a grant of stock options. The Form 4 reports an award of 18,000 stock options with an exercise price of $23.67, dated 09/22/2025. The options have an exercise price of $23.67 and underlying 18,000 shares of common stock, with an expiration date of 09/21/2035.
The filing states the option vests monthly as to 1/9 of the total award, beginning with a first tranche vesting on 10/01/2025, subject to continued service. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/24/2025.
Kathiresan Sekar, a director of Maze Therapeutics, Inc. (MAZE), reported the acquisition on 09/22/2025 of a stock option to buy 18,000 shares of common stock with an exercise price of $23.67. The option award vests in nine equal monthly tranches (1/9 each) beginning October 1, 2025, subject to continued service. The option shows an expiration or related date of 09/21/2035 and is reported as direct beneficial ownership. The Form 4 was signed by an attorney-in-fact, Courtney Phillips, on 09/24/2025.
Maze Therapeutics director Charles J. Homcy was granted a stock option to buy 18,000 shares of Maze Therapeutics common stock at an exercise price of $23.67 per share. The option is reported as a direct holding and covers 18,000 underlying shares with an exercise/expiration reference shown as 09/21/2035. The option vests monthly as to 1/9 of the award, with the first tranche vesting on October 1, 2025, subject to the holder’s continued service.
The grant increases the reporting person’s beneficial ownership by 18,000 shares on the reported transaction date of September 22, 2025. No cash exercise is indicated in the filing and the option is described as a right to buy common stock under standard vesting conditions tied to continued service.
Maze Therapeutics director Neil Exter was granted a stock option to buy 18,000 shares of Maze Therapeutics, Inc. (MAZE) at an exercise price of $23.67 per share. The option was granted on 09/22/2025, is exercisable beginning 09/21/2025, and expires 09/21/2035. The award vests in nine equal monthly tranches (1/9 each) with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service. The Form 4 was signed on 09/24/2025 by an attorney-in-fact.